Patent Licensing: Exclusive, Non-Exclusive, and Compulsory Licenses

Patent licensing is the legal mechanism by which patent holders grant others the right to use, make, sell, or import a patented invention without transferring ownership of the underlying patent. This page covers the three principal license structures — exclusive, non-exclusive, and compulsory — examining their legal definitions, operational mechanics, regulatory framing under Title 35 of the U.S. Code, and the strategic tradeoffs each structure creates for licensors and licensees. The distinctions between license types carry significant legal and economic consequences, including effects on standing to sue for infringement, royalty structures, and market exclusivity.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps
• Reference table or matrix
• References

Definition and scope

Patent licensing operates within the framework established by Title 35 of the U.S. Code, specifically 35 U.S.C. § 261, which explicitly treats patents as personal property assignable and licensable in writing. A license, as distinguished from an assignment, conveys a contractual permission rather than a transfer of title — the patent remains owned by the licensor throughout the license term.

The USPTO administers patent grants and records assignments and exclusive licenses that are submitted for recordation, but the agency does not regulate license terms between private parties. License terms are instead governed by contract law, with courts — primarily the U.S. Court of Appeals for the Federal Circuit — resolving disputes over scope, breach, and enforceability. The broader regulatory context for patent law includes interactions with antitrust doctrine, where the Department of Justice (DOJ) Antitrust Division and Federal Trade Commission (FTC) assess whether licensing practices constitute anticompetitive conduct under 15 U.S.C. § 1 (Sherman Act).

A patent license is defined by 4 core parameters: the scope of rights granted (make, use, sell, import), the field of use, the geographic territory, and the exclusivity status. Each parameter can be restricted or expanded independently, producing a combinatorially large space of possible license configurations.

For a broader orientation to patent rights as a system, the Patent Law Authority index provides foundational context on how patent rights arise and what they protect.

Core mechanics or structure

Exclusive licenses grant a single licensee the right to exercise one or more patent rights to the exclusion of all others, including — if the license so specifies — the patent owner itself. Exclusivity can be total (all rights, all fields, all territories) or partial (a defined field of use, a defined geography, or a defined time window). Under Federal Circuit doctrine established in Waterman v. Mackenzie, 138 U.S. 252 (1891), an exclusive licensee who holds all substantial rights in a patent acquires standing to sue for infringement in its own name without joining the patent owner.

Non-exclusive licenses grant the licensee permission to practice the invention while the licensor retains the right to grant identical or overlapping licenses to other parties. A non-exclusive licensee does not acquire independent standing to sue for infringement — that right remains with the patent owner (35 U.S.C. § 281). Non-exclusive licenses are commonly structured as royalty-bearing agreements, though fully paid-up non-exclusive licenses (sometimes called covenant-not-to-sue instruments) are also used in cross-licensing and patent pool arrangements.

Compulsory licenses are government-ordered or government-authorized grants of patent rights to a third party, typically without requiring the patent owner's consent. In the United States, compulsory licensing operates through 3 primary statutory mechanisms:

1. 28 U.S.C. § 1498 — authorizes the federal government and its contractors to use a patented invention without the owner's consent, with the patent holder's remedy limited to reasonable compensation.
2. 35 U.S.C. § 203 — applies to inventions arising from federally funded research under the Bayh-Dole Act; the funding agency can require licensing if the patent holder fails to bring the invention to practical application.
3. Atomic Energy Act and Clean Air Act — contain sector-specific compulsory licensing provisions.

The U.S. does not have a general pharmaceutical compulsory licensing statute of the type found in other jurisdictions, though the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement framework (WTO TRIPS Agreement, Article 31) provides the international structure under which WTO members may issue such licenses for public health emergencies.

Causal relationships or drivers

License type selection is driven by the intersection of market structure, patent portfolio strategy, and litigation risk. Patent holders with a single commercially dominant invention typically prefer exclusive licensing to one licensee at a premium royalty rate — this maximizes per-license revenue and provides the licensee with a defensible market position. Patent holders with broad portfolios often prefer non-exclusive licensing at lower per-unit royalties across a large licensee base, trading exclusivity for volume and market-clearing efficiency.

Compulsory licensing is triggered by specific regulatory or statutory conditions rather than market choice. Under the Bayh-Dole Act (35 U.S.C. §§ 200–212), march-in rights allow the funding federal agency to require licensing if the patent holder has not taken effective steps to achieve practical application of the invention within a reasonable time. As of 2024, no federal agency had successfully exercised march-in rights to compel licensing, a record documented by the Government Accountability Office.

Antitrust enforcement also shapes license structure. The DOJ and FTC Antitrust Guidelines for the Licensing of Intellectual Property (2017) address how exclusive dealing, field-of-use restrictions, and package licensing are analyzed for competitive effects.

Classification boundaries

The distinction between a license and an assignment is legally decisive. Under 35 U.S.C. § 261, an assignment transfers ownership; a license transfers only a subset of rights. When an "exclusive license" conveys all substantial rights — including the right to sublicense and the right to exclude the licensor — courts treat it as an assignment in substance, regardless of its label. This classification matters for standing, tax treatment, and bankruptcy proceedings.

The boundary between exclusive and non-exclusive licenses turns on the presence or absence of a covenant that the licensor will not grant identical rights to a third party. A "sole license" — a variant where only one licensee exists but the licensor retains the right to practice the patent itself — occupies an intermediate position: it is exclusive against other potential licensees but not against the licensor.

Field-of-use restrictions create sub-licenses that are exclusive within a defined technical or commercial domain while non-exclusive at the patent level overall. Federal Circuit case law treats these field-limited exclusive licenses as exclusive for standing purposes only within their defined field.

For pharmaceutical patents, the relationship between patent licensing and regulatory exclusivity periods under Hatch-Waxman (21 U.S.C. § 355(j)) requires separate analysis, as drug approval-based exclusivity operates independently from patent license terms.

Tradeoffs and tensions

Revenue versus control. Exclusive licenses command higher upfront payments and royalties but eliminate the licensor's ability to license competing parties. Non-exclusive licenses preserve that flexibility at the cost of per-licensee revenue.

Enforcement burden. An exclusive licensee with full substantial rights inherits the burden and cost of patent enforcement. A non-exclusive licensee depends entirely on the licensor to sue infringers, creating a free-rider dynamic if the licensor is unwilling to litigate.

Sublicensing rights. Unless a license agreement expressly grants sublicensing authority, a licensee cannot sublicense the patent (35 U.S.C. § 261 requires written authority). Exclusive licensees frequently negotiate for sublicensing rights to enable downstream commercialization or to form joint ventures.

Compulsory licensing and investment incentive. The threat of compulsory licensing — even when rarely exercised — can suppress investment in R&D by reducing the expected return on patent rights. This tension is explicitly acknowledged in the TRIPS Agreement preamble, which recognizes the need to balance patent protection against public interest, particularly in access to medicines.

Bankruptcy risk. Under 11 U.S.C. § 365(n), a licensee retains its license rights if a licensor files for bankruptcy and the trustee rejects the license agreement, provided the licensee elects to retain those rights. This protection applies to intellectual property licenses but does not extend to all contractual rights associated with the license.

Common misconceptions

Misconception: Filing a license with the USPTO is required for it to be valid.
A patent license is enforceable between the parties as a contract regardless of whether it is recorded with the USPTO. Recording under 35 U.S.C. § 261 provides constructive notice to subsequent purchasers — it does not create or validate the license itself.

Misconception: A compulsory license means a patent owner receives no compensation.
U.S. compulsory licensing statutes require reasonable compensation. Under 28 U.S.C. § 1498, the federal government may use a patent but must pay the patent holder reasonable and entire compensation, with disputes resolved in the U.S. Court of Federal Claims.

Misconception: An exclusive licensee can always sue infringers independently.
Exclusivity alone is insufficient to confer standing. Federal Circuit doctrine requires that the licensee hold "all substantial rights" — including the right to sue — before it can bring an infringement action without joining the patent owner. A field-limited or territory-limited exclusive licensee typically lacks that standing outside the defined scope.

Misconception: Non-exclusive licenses cannot be transferred.
License transferability depends entirely on contract terms. Without an express prohibition, the general common-law rule for patent licenses holds that non-exclusive licenses are personal and non-transferable — but this default can be and frequently is modified by the agreement.

Checklist or steps

The following sequence describes the structural components typically present in a patent license transaction. This is an informational framework describing common practice, not a prescription for any specific transaction.

Phase 1 — Pre-agreement diligence
- [ ] Confirm patent ownership chain via USPTO assignment records
- [ ] Verify patent term: utility patents expire 20 years from earliest effective filing date (35 U.S.C. § 154)
- [ ] Identify all patents in the licensed portfolio (related continuations, divisionals)
- [ ] Assess maintenance fee status — lapsed patents cannot be effectively licensed
- [ ] Review any existing encumbrances: prior licenses, security interests, government funding obligations under Bayh-Dole

Phase 2 — License structure determination
- [ ] Define exclusivity status (exclusive, sole, non-exclusive)
- [ ] Define field of use with precision to avoid scope disputes
- [ ] Define geographic territory
- [ ] Determine sublicensing rights
- [ ] Determine whether the licensor retains the right to practice

Phase 3 — Commercial terms
- [ ] Specify royalty base (net sales, units, revenue)
- [ ] Set royalty rate or upfront payment amounts
- [ ] Define audit rights and accounting periods
- [ ] Address minimum annual royalties or milestone payments

Phase 4 — Enforcement and term
- [ ] Allocate infringement enforcement responsibilities
- [ ] Define cure periods and termination triggers
- [ ] Address consequences of patent invalidation (e.g., royalty reduction clauses)
- [ ] Specify governing law and dispute resolution forum

Phase 5 — Recordation and compliance
- [ ] Determine whether recordation with the USPTO under 35 U.S.C. § 261 is warranted for constructive notice
- [ ] Confirm compliance with any government license rights if invention arose from federal funding

Reference table or matrix

Sources: 35 U.S.C. § 154; 35 U.S.C. § 261; 28 U.S.C. § 1498; 35 U.S.C. §§ 200–212 (Bayh-Dole Act)